Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02132611
Other study ID # CLN-0005-P
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 2014
Est. completion date June 2017

Study information

Verified date July 2023
Source Abbott Medical Devices
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the COAST clinical study data will be to utilize and to gain approval for commercializing the Micro Crown as part of the Coronary Orbital Atherectomy System (OAS).


Description:

This is a prospective, single-arm, multi-center, global study designed to evaluate performance of the Diamondback 360® Coronary Orbital Atherectomy System Micro Crown (OAS Micro Crown) in treating de novo, severely calcified coronary lesions.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date June 2017
Est. primary completion date September 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects must be 18 or older. - Subjects must have a clinical indication for coronary intervention. - CK and CK-MB must be less than or equal to the upper limit of lab normal value within 8 hours prior to the procedure. - The target lesion must be a de novo coronary lesion that has not been previously treated with any interventional procedure. - The target vessel must be a native coronary artery. - The target vessel reference diameter must be >= 2.5mm and <= 4.0 mm. - The lesion length must not exceed 40 mm. - The target vessel must have a TIMI flow three (3) at baseline. - The target lesion must have fluoroscopic, IVUS or OCT evidence of severe calcium deposit at the lesion site. - The lesion must be crossable with the study guide wire. Exclusion Criteria: - Inability to understand the study requirements or has a history of non-compliance with medical advice. - Unwilling to sign the COAST ICF. - History of any cognitive or mental health status that would interfere with study participation. - Currently enrolled in any other pre-approval investigational study. - Female subjects who are pregnant or planning to become pregnant within the study period. - Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel without adequate alternative medications. - Known sensitivity to contrast media, which cannot be adequately pre-medicated. - Diagnosed with chronic renal failure unless under hemodialysis, or has a serum creatinine level > 2.5 mg/dl. - Experienced acute MI, STEMI or non-STEMI: CK-MB greater than the upper limit of lab normal value, within 30 days prior to index procedure. - History of major cardiac intervention within 30 days. - Evidence of heart failure - History of a stroke or TIA within six (6) months. - Active peptic ulcer or upper GI bleeding within six (6) months. - History of bleeding diathesis or coagulopathy or intention to refuse blood transfusion, if one should become necessary. - Concurrent medical condition with a life expectancy of < 12 months. - History of immune deficiency. - Uncontrolled insulin dependent diabetes. - Evidence of active infections on the day of the index procedure. - Subject has planned cardiovascular intervention within 60 days post index procedure. - Subject is not an acceptable candidate for emergent CABG surgery. - Subject with known allergy to atherectomy lubricant components such as soybean oil, egg yolk phospholipids, glycerin and sodium hydroxide. - Subject with angiographically confirmed evidence of more than one (1) lesion requiring intervention, unless the treatment of the lesions is staged. - Target lesion is located in a native vessel distal to anastomosis with a saphenous vein graft or LIMA/RIMA bypass. - Target vessel has other lesions with greater than 50% diameter stenosis based on visual estimate or on-line QCA. - Target vessel has angiographically visible or suspected thrombus. - Target vessel has a stent from previous PCI. - Target vessel appears to be or is excessively tortuous at baseline. - Target lesion is an ostial location (within 5 mm of ostium) or an unprotected left main lesion. - Target lesion is a bifurcation. - Target lesion has a = 1.5 mm side branch. - Angiographic evidence of a dissection prior to initiation of OAD.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Diamondback 360® Coronary OAS Micro Crown
The Diamondback 360® Coronary OAS Micro Crown consists of a diamond-coated crown mounted to a shaft. The OAD ablates occlusive material in order to facilitate stent delivery. During orbit, forces press the crown against the coronary plaque, reducing calcified plaque on the vessel wall.

Locations

Country Name City State
Japan Shonan Kamakura General Hospital Kamakura-city Kanagawa
Japan Kyoto Katsura Hospital Kyoto Nishikyo-ku
Japan Miyazaki Medical Association Hospital Miyazaki-city Miyazaki
Japan Sapporo Higashi Tokushukai Hospital Sapporo-city Hokkaido
Japan Saiseikai Yokohamashi Tobu Hospital Yokohama-shi Kanagawa
United States Chandler Regional Medical Center and Mercy Gilbert Medical Center Chandler Arizona
United States Duke University Durham North Carolina
United States North Florida Regional Medical Center Gainesville Florida
United States Palm Beach Gardens Jupiter Florida
United States Columbia University Medical Center New York New York
United States Mount Sinai Hospital New York New York New York
United States Munroe Regional Health System, Inc. Ocala Florida
United States Florida Hospital Orlando Florida
United States NC Heart and Vascular Research Raleigh North Carolina
United States St. Francis Hospital Roslyn New York
United States Baptist Memorial Hospital/Stern Cardiovascular Foundation, Inc. Southaven Mississippi
United States Tallahassee Research Institute Tallahassee Florida

Sponsors (1)

Lead Sponsor Collaborator
Abbott Medical Devices

Countries where clinical trial is conducted

United States,  Japan, 

References & Publications (2)

Martinsen BJ, Kumar K, Saito S, Sharma SK, Ikeno F, Fearnot NE, Shlofmitz RA, Thatcher R, Krucoff MW. Japan-USA Orbital Atherectomy for Calcific Coronary Lesions: COAST Study, Harmonization by Doing Proof-of-Concept. Cardiovasc Revasc Med. 2022 Apr;37:112 — View Citation

Redfors B, Sharma SK, Saito S, Kini AS, Lee AC, Moses JW, Ali ZA, Feldman RL, Bhatheja R, Stone GW. Novel Micro Crown Orbital Atherectomy for Severe Lesion Calcification: Coronary Orbital Atherectomy System Study (COAST). Circ Cardiovasc Interv. 2020 Aug; — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Major Adverse Cardiac Event (MACE) A Kaplan-Meier analysis was performed to determine the percent probability that a study participant is free from major adverse cardiac events at 30 days.
30-Day MACE is composed of:
Cardiac death
Myocardial Infarction (MI) - defined as a Creatine Kinase Myocardial-Band Isoenzyme (CK-MB) level greater than three (3) times the Upper Limit of Lab Normal (ULN) value with or without new pathologic Q wave
Target Vessel Revascularization (TVR) - defined as a revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure
30 Days
Secondary Procedural Success Procedural success was defined as success in facilitating stent delivery with a residual stenosis of <50% and without the occurrence of an in-hospital MACE in de novo, severely calcified coronary lesions. Participants were followed from baseline procedure through the duration of hospital stay, an average of 50.4 hours
See also
  Status Clinical Trial Phase
Terminated NCT04459299 - CorPath GRX STEMI Study
Not yet recruiting NCT02853994 - Safety and Efficacy of the DEVOIR Sirolimus-Coated Coronary Balloon in the Real-world Clinical Practice N/A
Completed NCT02440893 - Understanding the Effect of Metformin on Corus CAD (or ASGES)
Completed NCT01486030 - Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
Recruiting NCT06239493 - IVUS-Guided Treatment for Percutaneous Vascular Interventions
Recruiting NCT05344612 - Comparing a Diagnostic and Treatment Strategy of Upfront CTCA With SOC in Patients With Chest Pain and Suspected CAD N/A
Terminated NCT03901079 - Trial for A Novel Facilitated Antegrade Steering Technique in Revascularization of Coronary Chronic Total Occlusions
Completed NCT02457455 - Urgent Medical and Surgical Conditions During Flights N/A
Recruiting NCT05509010 - AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry
Completed NCT03930589 - Remote Ischemic Conditioning in STEMI to Decrease Infarct Size N/A
Completed NCT01251302 - Utility of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Cardiology Practice Pattern
Withdrawn NCT02158754 - Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making
Completed NCT01949844 - Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies N/A
Recruiting NCT04787796 - The Application of a Portable Multichannel ECG System for the Patients Suspected to Have Possible CAD or ACS N/A
Recruiting NCT03894423 - Comprehensive Computed Tomography Guidance of Coronary Bypass Graft Surgery
Completed NCT02223286 - Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making N/A
Completed NCT06154018 - Heparin Reversal With Two Different Protamine Ratios After Cardiopulmonary By-pass. N/A
Completed NCT01406990 - Aspirin Responsiveness in Women With Coronary Artery Disease N/A
Completed NCT01402804 - NSAIDs in Coronary Artery Disease Patients N/A
Completed NCT00500617 - Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree